Cancer Research and Treatment

Original Articles

Hematologic malignancy

A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK: Sora Kang, Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Yoon Sei Lee, Chan-Sik Park, Heounjeong Go, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Seok Jin Kim, Won Seog Kim, Sang Eun Yoon, Young Hyeh Ko, Cheolwon Suh; Cancer Res Treat. 2023;55(1):314-324. Published online March 31, 2022; DOI: https://doi.org/10.4143/crt.2022.015

Abstract PDF Supplementary Material PubReader ePub

Purpose
Prognostic Index for Natural Killer Lymphoma (PINK) is the most widely accepted prognostic model for patients withextranodal natural killer/T-cell lymphoma (ENKTL) treated with non-anthracycline–based therapy. We aimed to evaluate the prognostic implications of serum β-2 microglobulin (β2M) in the context of PINK and proposed a new prognostic model.
Materials and Methods
A total of 138 patients who were newly diagnosed with ENKTL and treated with non-anthracycline-based chemotherapy were identified. The cut-off value of high serum β2M was calculated by maximal-chi square methods (4.1 mg/L). A new prognostic model incorporating serum β2M into PINK was proposed and validated in an independent validation cohort (n=88).
Results
The patients’ median age was 53.5 years (range, 19 to 80 years). Patients with high serum β2M levels had significantly worse overall survival (OS) and progression-free survival (PFS). In multivariate analysis, high serum β2M was an independent adverse prognostic factor for OS. A new PINK-B (Prognostic Index for Natural Killer Lymphoma-serum β-2 microglobulin) model stratifiedpatients into three groups with distinct OS and PFS in the training cohort (3-year OS, 84.1% [95% confidence interval, 75.1 to 94.2], 46.8% [36.1 to 60.8] and 17.6% [6.3 to 49.2] for the low-, intermediate, and high-risk groups, respectively; 3-year PFS, 70.6% [59.4 to 83.8], 35.9% [25.9 to 49.8], and 7.35% [1.1 to 46.7] for the low-, intermediate-, and high-risk groups, respectively). The PINK-B model was further validated in an independent cohort.
Conclusion
Serum β2M is an independent prognostic factor for ENKTL patients. The new serum β2M-based prognostic model may be useful for identifying ultra-high-risk patients, and it can easily be adopted into daily clinical practice.

Citations

Citations to this article as recorded by

Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma
Yun Hui, Yingjun Gao, Jiawei Li, Qingtao Kong, Yuanyuan Duan, Haibo Liu, Fang Liu, Hong Sang
Annals of Hematology.2024; 103(4): 1285. CrossRef
Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
Theodoros P. Vassilakopoulos, Maria Arapaki, Panagiotis T. Diamantopoulos, Athanasios Liaskas, Fotios Panitsas, Marina P. Siakantaris, Maria Dimou, Styliani I. Kokoris, Sotirios Sachanas, Marina Belia, Chrysovalantou Chatzidimitriou, Elianna A. Konstantin
Cancers.2024; 16(2): 238. CrossRef
Prognostic Value of18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma
Yu Luo, Zhun Huang, Zihan Gao, Bingbing Wang, Yanwei Zhang, Yan Bai, Qingxia Wu, Meiyun Wang
Korean Journal of Radiology.2024; 25(2): 189. CrossRef
A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase
Ziyuan Shen, Xudong Zhang, Yujie Li, Xicheng Chen, Xing Xing, Hao Zhang, Jingjing Ye, Ling Wang, Tao Jia, Taigang Zhu, Yuqing Miao, Chunling Wang, Hui Liu, Liang Wang, Wei Sang
Future Oncology.2024; 20(28): 2071. CrossRef

4,846 View
129 Download
5 Web of Science
4 Crossref

Hematologic Malignancy

Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels: Hyung-Don Kim, Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Chan-Sik Park, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Dok-Hyun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim, Cheolwon Suh; Cancer Res Treat. 2021;53(3):847-856. Published online December 17, 2020; DOI: https://doi.org/10.4143/crt.2020.1060

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to investigate the prognostic value of serum β2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system.
Materials and Methods
A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and/or serum β2-microglobulin levels. A risk-stratifying classification system incorporating serum β2-microglobulin levels was proposed and validated in an independent validation cohort (n=60).
Results
The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum β2-microglobulin levels (> 2 mg/L) had significantly worse progression-free survival (PFS) and overall survival (OS) (p < 0.01 for both). Serum β2-microglobulin levels further stratified patients in the low-risk and high-risk groups in terms of PFS (p=0.010 and p=0.044, respectively) and OS (p=0.014 and p=0.026, respectively). Multivariate analyses revealed that a high serum β2-microglobulin level (> 2 mg/L) was independently associated with a shorter PFS (hazards ratio [HR], 3.56; p=0.047) and OS (HR, 4.66; p=0.043). The new classification system incorporating the serum β2-microglobulin level allowed the stratification of patients into three distinct risk subgroups with 5-year OS rates of 100%, 89.5%, and 62.5%. In an independent cohort of BL, the system was validated by stratifying patients with different survival outcomes.
Conclusion
Serum β2-microglobulin level is an independent prognostic factor for BL patients. The proposed β2-microglobulin–based classification system could stratify patients with distinct survival outcomes, which may help define appropriate treatment approaches for individual patients.

Citations

Citations to this article as recorded by

The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients
Ze Jin, Yi Miao, Jie Zhang, Jing Zhang, Chunling Wang, Xuzhang Lu, Yuqing Miao, Miao Sun, Yunping Zhang, Yun Zhuang, Haiwen Ni, Jingyan Xu, Wanchuan Zhuang, Min Zhao, Jianfeng Zhu, Min Xu, Guoqiang Lin, Haiying Hua, Xiaoyan Xie, Maozhong Xu, Tao Jia, Liji
Annals of Hematology.2024; 103(7): 2257. CrossRef
Prognostic Value of18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma
Yu Luo, Zhun Huang, Zihan Gao, Bingbing Wang, Yanwei Zhang, Yan Bai, Qingxia Wu, Meiyun Wang
Korean Journal of Radiology.2024; 25(2): 189. CrossRef
The Role of Beta2-Microglobulin in Central Nervous System Disease
Zhen-Yuan Liu, Feng Tang, Jin-Zhou Yang, Xi Chen, Ze-Fen Wang, Zhi-Qiang Li
Cellular and Molecular Neurobiology.2024;[Epub] CrossRef
Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients: a preliminary clinical study
Zhen-Yuan Liu, Feng Tang, Jing Wang, Jin-Zhou Yang, Xi Chen, Ze-Fen Wang, Zhi-Qiang Li
BMC Cancer.2024;[Epub] CrossRef
Serum beta2-microglobulin and peripheral blood eosinophils for the assessment of severity and prognosis with omicron variant COVID-19 infection
Jie Tan, Hanxi Fang, Xiao Hu, Ming Yue, Junling Yang
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis
Zhentian Wu, Chenyi Wang, Yao Lyu, Zheshen Lin, Ming Lu, Shixiong Wang, Bingxuan Wang, Na Yang, Yeye Li, Jianhong Wang, Xiaohui Duan, Na Zhang, Jing Gao, Yuan Zhang, Miaowang Hao, Zhe Wang, Guangxun Gao, Rong Liang
Frontiers in Oncology.2023;[Epub] CrossRef
Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma
Ning-Chun Chen, Hung Chang, Hsiao-Wen Kao, Che-Wei Ou, Ming-Chung Kuo, Po-Nan Wang, Tung-Liang Lin, Jin-Hou Wu, Yu-Shin Hung, Yi-Jiun Su, Yuen-Chin Ong, Hsuan-Jen Shih
Clinical and Experimental Medicine.2023; 23(7): 3759. CrossRef
Tuberculosis combined with Burkitt lymphoma in a kidney transplant recipient: A case report and literature review
Jian-Nan Hu, Mu-Qing Yu, Li-Juan Hua, Chen Bao, Qian Liu, Chao Liu, Zi-Ling Li, Xi Wang, Shu-Yun Xu
Medicine.2023; 102(18): e33671. CrossRef
Elevated serum beta-2 microglobulin level predicts short-term poor prognosis of patients with de novo acute omicron variant COVID-19 infection
Shengping Gong, Ruishuang Ma, Ting Zhu, Xiaoqin Ge, Rongrong Xie, Qingsong Tao, Cong Shi
Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers
Yajiao Liu, Li Sheng, Haiying Hua, Jingfen Zhou, Ying Zhao, Bei Wang
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified
Hyung-Don Kim, Hyungwoo Cho, Byeong Seok Sohn, Chan-Sik Park, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim, Cheolwon Suh
Leukemia & Lymphoma.2022; 63(1): 124. CrossRef

5,857 View
149 Download
11 Web of Science
11 Crossref

Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers: Jeong Mo Bae, Xianyu Wen, Tae-Shin Kim, Yoonjin Kwak, Nam-Yun Cho, Hye Seung Lee, Gyeong Hoon Kang; Cancer Res Treat. 2020;52(1):74-84. Published online May 8, 2019; DOI: https://doi.org/10.4143/crt.2019.062

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to reveal the clinicopathological characteristics and prognostic implications associated with fibroblast growth factor receptor 1 (FGFR1) amplification in colorectal cancers (CRCs).
Materials and Methods
We measured the copy number of FGFR1 by droplet digital polymerase chain reaction (ddPCR), and analyzed the FGFR1 expression by immunohistochemistry, in 764 surgically resected CRCs (SNUH2007 dataset, 384 CRCs; SNUH Folfox dataset, 380 CRCs).
Results
CRCs with ≥ 3.3 copies of the FGFR1 gene were classified as FGFR1 amplified. FGFR1 amplification was found in 10 of the 384 CRCs (2.6%) in the SNUH2007 dataset, and in 28 of the 380 CRCs (7.4%) in the SNUH Folfox dataset. In the SNUH2007 dataset, there was no association between the FGFR1 copy number status and sex, gross appearance, stage, or differentiation. High FGFR1 expression was associated with female sex and KRAS mutation. At the molecular level, FGFR1 amplification was mutually exclusive with BRAF mutation, microsatellite instability, and MLH1 methylation, in both SNUH2007 and SNUH Folfox datasets. Survival analysis revealed that FGFR1 amplification was associated with significantly worse clinical outcome compared with no FGFR1 amplification, in both SNUH2007 and SNUH Folfox datasets. Within the SNUH2007 dataset, CRC patients with high FGFR1 expression had an inferior progression-free survival compared with those with low FGFR1 expression. The FGFR inhibitor, PD173074, repressed the proliferation of a CRC cell line overexpressing FGFR1, but not of cells with FGFR1 amplification.
Conclusion
FGFR1 amplification measured by ddPCR can be a prognostic indicator of poor clinical outcome in patients with CRCs.

Citations

Citations to this article as recorded by

A panorama of colon cancer in the era of liquid biopsy
Sylvie Devalle, Veronica Aran, Cesar de Souza Bastos Júnior, Vera Lucia Pannain, Paulo Brackmann, Marcelo Leal Gregório, José Eduardo Ferreira Manso, Vivaldo Moura Neto
The Journal of Liquid Biopsy.2024; 4: 100148. CrossRef
Targeting FGFR1 by β,β-dimethylacrylalkannin suppresses the proliferation of colorectal cancer in cellular and xenograft models
Ran Zhao, Fanxiang Yin, Mangaladoss Fredimoses, Jianhua Zhao, Xiaorong Fu, Beibei Xu, Mengrui Liang, Hanyong Chen, Kangdong Liu, Mingjuan Lei, Kyle Vaughn Laster, Zhi Li, Joydeb Kumar Kundu, Zigang Dong, Mee-Hyun Lee
Phytomedicine.2024; 129: 155612. CrossRef
Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies
César Gutiérrez Pérez, Enrique Lastra Aras, Patricia Saiz López, Enrique García Toro, Carmen Blanco Abad, Inmaculada Rodríguez Ledesma, María Pumares González, Miriam Vela Domínguez, Noelia Espinosa Cabria, Guillermo Crespo Herrero
Clinical and Translational Oncology.2024;[Epub] CrossRef
Diphenyl urea‐benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents
Heba T. Abdel‐Mohsen, Amira M. Nageeb, Iman A. Y. Ghannam
Drug Development Research.2024;[Epub] CrossRef
Clinical evaluation of a droplet digital PCR assay for detecting POLE mutations and molecular classification of endometrial cancer
Gilhyang Kim, Song Kook Lee, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim, Hyojin Kim
Journal of Gynecologic Oncology.2022;[Epub] CrossRef
Detection and Quantification of Stagonosporopsis cucurbitacearum in Seeds of Cucurbita maxima Using Droplet Digital Polymerase Chain Reaction
Sergio Murolo, Marwa Moumni, Valeria Mancini, Mohamed Bechir Allagui, Lucia Landi, Gianfranco Romanazzi
Frontiers in Microbiology.2022;[Epub] CrossRef
Fibroblast growth factor 2: Role in prenatal alcohol-induced stimulation of hypothalamic peptide neurons
Guo-Qing Chang, Nushrat Yasmin, Adam D. Collier, Olga Karatayev, Nailya Khalizova, Amanda Onoichenco, Milisia Fam, Avi S. Albeg, Samantha Campbell, Sarah F. Leibowitz
Progress in Neuro-Psychopharmacology and Biological Psychiatry.2022; 116: 110536. CrossRef
Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer
Elaine S. Tan, Todd C. Knepper, Xuefeng Wang, Jennifer B. Permuth, Liang Wang, Jason B. Fleming, Hao Xie
Cancers.2022; 14(9): 2223. CrossRef
Tumor-induced Osteomalacia: A Systematic Review and Individual Patient’s Data Analysis
Domenico Rendina, Veronica Abate, Giuseppe Cacace, Lanfranco D’Elia, Gianpaolo De Filippo, Silvana Del Vecchio, Ferruccio Galletti, Alberto Cuocolo, Pasquale Strazzullo
The Journal of Clinical Endocrinology & Metabolism.2022; 107(8): e3428. CrossRef
Indications of Genomic Abnormalities for Molecular Targeted Therapy in Colorectal Cancer
Koshi Mimori
Nippon Daicho Komonbyo Gakkai Zasshi.2022; 75(10): 449. CrossRef
Onco-ontogeny recapitulates phylogeny – a consideration
P. N. Plowman, C. E. Plowman
Oncogene.2021; 40(8): 1542. CrossRef
Integrating Multi–Omics Data for Gene-Environment Interactions
Yinhao Du, Kun Fan, Xi Lu, Cen Wu
BioTech.2021; 10(1): 3. CrossRef
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Guihong Liu, Tao Chen, Zhenyu Ding, Yang Wang, Yuquan Wei, Xiawei Wei
Cell Proliferation.2021;[Epub] CrossRef
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Harriet R. Ferguson, Michael P. Smith, Chiara Francavilla
Cells.2021; 10(5): 1201. CrossRef
Identification of Prognostic Dosage-Sensitive Genes in Colorectal Cancer Based on Multi-Omics
Zhiqiang Chang, Xiuxiu Miao, Wenyuan Zhao
Frontiers in Genetics.2020;[Epub] CrossRef
Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients

Jianxia Li, Jianwei Zhang, Huabin Hu, Yue Cai, Jiayu Ling, Zehua Wu, Yanhong Deng
Cancer Management and Research.2020; Volume 12: 3301. CrossRef
Identification of Genomic Alterations of Perineural Invasion in Patients with Stage II Colorectal Cancer

Hao Su, Chen Chang, Jiajie Hao, Xin Xu, Mandula Bao, Shou Luo, Chuanduo Zhao, Qian Liu, Xishan Wang, Zhixiang Zhou, Haitao Zhou
OncoTargets and Therapy.2020; Volume 13: 11571. CrossRef
Design, Synthesis and Biological Evaluation: 5-amino-1H-pyrazole-1- carbonyl derivatives as FGFR Inhibitors
Yan Zhang, Niefang Yu
Letters in Drug Design & Discovery.2020; 17(11): 1330. CrossRef

8,232 View
298 Download
17 Web of Science
18 Crossref

Outcome and Prognostic Factors for ETV6/RUNX1 Positive Pediatric Acute Lymphoblastic Leukemia Treated at a Single Institution in Korea: Jae Wook Lee, Seong-koo Kim, Pil-Sang Jang, Nack-Gyun Chung, Dae-Chul Jeong, Myungshin Kim, Bin Cho, Hack-Ki Kim; Cancer Res Treat. 2017;49(2):446-453. Published online August 10, 2016; DOI: https://doi.org/10.4143/crt.2016.211

Abstract PDF Supplementary Material PubReader ePub

Purpose
ETV6/RUNX1 (+) acute lymphoblastic leukemia (ALL), which is the most common genetic subtype of pediatric ALL, has a favorable prognosis. In this study, we analyzed the outcome of ETV6/RUNX1 (+) ALL patients treated at our institution with the aim of identifying significant prognostic variables.
Materials and Methods
Sixty-three patients were diagnosed with ETV6/RUNX1 (+) ALL from 2005 to 2011. Prognostic variables studied included minimal residual disease (MRD) as detected by ETV6/RUNX1 (+) fusion, and the presence of additional cytogenetic abnormalities.
Results
The 5-year event-free survival was 84.1±4.6%, with 10 patients relapsing at a median of 28.3 months from diagnosis for a 5-year cumulative incidence of relapse of 15.9±4.6%. Multivariate analysis revealed that the presence MRD, as detected by real-time quantitative-polymerase chain reaction or fluorescence in situ hybridization for ETV6/RUNX1 fusion at end of remission induction, and the presence of additional structural abnormalities of 12p (translocations or inversions) negatively affected outcome. Despite treatment such as allogeneic hematopoietic cell transplantation, eight of the 10 relapsed patients died from disease progression for overall survival of 82.5±6.9%.
Conclusion
ETV6/RUNX1 ALL may be heterogeneous in terms of prognosis, and variables such as MRD at end ofremission induction or additional structural abnormalities of 12p could define a subset of patients who are likely to have poor outcome.

Citations

Citations to this article as recorded by

Outcome and Prognostic Factors of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia
Guan-hua Hu, Xiao-hui Zhang, Kai-yan Liu, Lan-ping Xu, Yu Wang, Yi-fei Cheng, Xiao-jun Huang
Acta Haematologica.2024; 147(5): 534. CrossRef
Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia
Jae Wook Lee, Seongkoo Kim, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho
Cancer Research and Treatment.2021; 53(2): 567. CrossRef
Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children’s Leukemia Group
Kun-yin Qiu, Hong-gui Xu, Xue-qun Luo, Hui-rong Mai, Ning Liao, Li-hua Yang, Min-cui Zheng, Wu-qing Wan, Xue-dong Wu, Ri-yang Liu, Qi-wen Chen, Hui-qin Chen, Xiao-fei Sun, Hua Jiang, Xing-jiang Long, Guo-hua Chen, Xin-yu Li, Chang-gang Li, Li-bin Huang, Y
Frontiers in Oncology.2021;[Epub] CrossRef
ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol
Yu Wang, Hui-min Zeng, Le-ping Zhang
Italian Journal of Pediatrics.2018;[Epub] CrossRef
Prognostic factors and treatment of pediatric acute lymphoblastic leukemia
Jae Wook Lee, Bin Cho
Korean Journal of Pediatrics.2017; 60(5): 129. CrossRef
ETV6 and ETV7: Siblings in hematopoiesis and its disruption in disease
Parisa Rasighaemi, Alister C. Ward
Critical Reviews in Oncology/Hematology.2017; 116: 106. CrossRef
Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse
Congcong Sun, Lixian Chang, Xiaofan Zhu
Oncotarget.2017; 8(21): 35445. CrossRef

12,744 View
282 Download
5 Web of Science
7 Crossref

Case Report

Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient: Eunji Choi, Jae-Cheol Jo, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Jooryung Huh, Chan-Sik Park, Sang Wook Lee, Cheolwon Suh; Cancer Res Treat. 2015;47(3):539-543. Published online September 11, 2014; DOI: https://doi.org/10.4143/crt.2013.245

Abstract PDF PubReader ePub

Here we report a case of a 76-year-old man with diffuse large B-cell lymphoma (DLBCL) with simultaneous involvement of the right breast and left testicle. The patient underwent complete resection of the involved testis, followed by immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) and prophylactic radiotherapy to the contralateral testis. Following this multimodal therapy, he achieved a complete response. This is a rare case of DLBCL involving both the breast and the testis in a male patient.

Citations

Citations to this article as recorded by

Rare incidence of diffuse large B-cell lymphoma (DLBCL) with bilateral breast and testicular involvement in a male patient: A case report and review of the literature
Sarah Ayad, Anuraag Sah, Kirolos Gergis, Michelle Cholankeril
Current Problems in Cancer: Case Reports.2022; 5: 100142. CrossRef
Primary breast lymphoma in males: Incidence, demographics, prognostic factors, survival, and comparisons with females
Jie Zhang, Binbin Ma, Hong Ji, Rong Guo
Frontiers in Surgery.2022;[Epub] CrossRef
Diffuse Large B-Cell Breast Lymphoma: A Case Series
Afaf H Al Battah, Einas A Al Kuwari, Zsolt Hascsi, Abdulqadir J Nashwan, Halima Elomari, Hisham Elsabah, Safa Al Azawi, Samah Kohla, Dina Soliman, Mohamed A Yassin
Clinical Medicine Insights: Blood Disorders.2017; 10: 1179545X1772503. CrossRef

11,958 View
68 Download
3 Web of Science
3 Crossref

Original Articles

Prognostic Factors in Non-Hodgkin's Lymphoma Patients Treated by Autologous Stem Cell Transplantation: A Single Center Experience: Cheolwon Suh, Sang Hee Kim, Hyo Jung Kim, Geundoo Jang, Eun Kyung Kim, Ok Bae Ko, Shin Kim, Hee Jung Sohn, Jung Shin Lee, M. Wookun Kim, Jooryung Huh; Cancer Res Treat. 2005;37(5):294-301. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.294

Abstract PDF PubReader ePub

Purpose

Autologous stem cell transplantation (ASCT) is increasingly used in patients with non-Hodgkin's lymphoma (NHL). Various clinical parameters-were evaluated to obtain significant predictors of the outcome following ASCT in patients with NHL.

Materials and Methods

Between April 1994 and December 2003, ASCT was performed on 80 patients with NHL at the Asan Medical Center.

Results

Patients had various histological subtypes and disease status. The two year progression free survival (PFS) and overall survival for all patients were 34 and 31%, respectively. A univariate analysis showed the performance status, stage, modified extranodal involvement category, International Prognostic Index (IPI) at mobilization, disease status at mobilization, and history of radiation prior to mobilization as significant predictors of the outcome following ASCT. Four risk groups, with different 2 year PFS, were identified by the age adjusted IPI at mobilization (mAAIPI): low risk 44%; low intermediate risk 40%; high intermediate risk 19%; and high risk 0% (p=.0003). A multivariate analysis revealed 3 significant factors for the PFS: disease status, prior RT and mAAIPI.

Conclusion

The mAAIPI was found to be an independent predictor of the outcome of NHL patients undergoing ASCT. This powerful prognostic tool should be used to evaluate potential candidates for ASCT.

Citations

Citations to this article as recorded by

Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Jung Sun Park, Cheolwon Suh
The Korean Journal of Medicine.2021; 96(6): 501. CrossRef
Disease characteristics of diffuse large B‐cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience
Daria Gaut, Tahmineh Romero, David Oveisi, Grant Howell, Gary Schiller
Hematological Oncology.2020; 38(1): 38. CrossRef
Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement
Ock Bae Ko, Geundoo Jang, Shin Kim, Jooryung Huh, Cheolwon Suh
The Korean journal of internal medicine.2008; 23(4): 182. CrossRef

9,285 View
47 Download
3 Crossref

High-Dose Chemotherapy of Cyclophosphamide, Thiotepa and Carboplatin (CTCb) followed by Autologous Stem-Cell Transplantation as a Consolidation for Breast Cancer Patients with 10 or more Positive Lymph Nodes: a 5-Year follow-Up Results: Hee-Jung Sohn, Sang-Hee Kim, Gyeong-Won Lee, Shin Kim, Jin-Hee Ahn, Sung-Bae Kim, Sang-We Kim, Woo Kun Kim, Cheolwon Suh; Cancer Res Treat. 2005;37(3):137-142. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.137

Abstract PDF PubReader ePub

Purpose

The benefit of consolidation high-dose chemotherapy (HDC) for high-risk primary breast cancer is controversial. We evaluated the efficacy and safety of consolidation HDC with cyclophosphamide, thiotepa and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) in resected breast cancer patients with 10 or more positive lymph nodes.

Materials and Methods

Between December 1994 and April 2000, 22 patients were enrolled. All patients received 2 to 6 cycles of adjuvant chemotherapy after surgery for breast cancer. The HDC regimen consisted of cyclophosphamide 1,500 mg/m²/day, thiotepa 125 mg/m²/day and carboplatin 200 mg/m²/day intravenous for 4 consecutive days.

Results

With a median follow-up of 58 months, 11 patients recurred and died. The median disease-free survival (DFS) and median overall survival (OS) were 49 and 69 months, respectively. The 5-year DFS and OS rates were 50% and 58%, respectively. The 12 patients with 10 to 18 involved nodes had better 5-year DFS (67%) and OS (75%) than 10 patients with more than 18 involved nodes (30% and 38%, respectively). The most common grade 3 or 4 nonhematologic toxicity was diarrhea, which occurred in 5 patients (23%). No treatment-related death was observed.

Conclusion

Consolidation HDC with CTCb followed by ASCT for resected breast cancer with more than 10 positive nodes had an acceptable toxicity but does not show promising survival.

Citations

Citations to this article as recorded by

Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Jung Sun Park, Cheolwon Suh
The Korean Journal of Medicine.2021; 96(6): 501. CrossRef
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
X. Wang, J. Ren, J. Zhang, Y. Yan, N. Jiang, J. Yu, L. Di, G. Song, L. Che, J. Jia, X. Zhou, H. Yang, H. K. Lyerly
Clinical and Translational Oncology.2016; 18(1): 82. CrossRef

9,076 View
45 Download
2 Crossref

High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Followed by Autologous Stem-Cell Transplantation for Metastatic Breast Cancer Patients: A 6-Year Follow-Up Result: Hee-Jung Sohn, Sang-Hee Kim, Gyeong-Won Lee, Shin Kim, Hye Jin Kang, Jin-Hee Ahn, Sung-Bae Kim, Sang-We Kim, Woo Kun Kim, Cheolwon Suh; Cancer Res Treat. 2005;37(1):24-30. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.24

Abstract PDF PubReader ePub

Purpose

The benefit of high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) is controversial. We evaluated the efficacy and safety of HDC with cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) for MBC patients.

Materials and Methods

From September 1994 to December 1999, 23 MBC patients were enrolled. All the patients received 2 to 10 cycles of induction chemotherapy. Before transplantation, 12 patients were in complete response (CR), nine were in partial response (PR), and two had progressive disease (PD). The HDC regimen consisted of cyclophosphamide 1,500 mg/m²/day, thiotepa 125 mg/m²/day and carboplatin 200 mg/m²/day intravenously for 4 consecutive days.

Results

After ASCT, 13 patients (56%) had a CR, five (22%) had a PR, three (13%) had no change, while two (9%) showed a PD. Seventeen patients relapsed or progressed during the median follow-up of 78 months. The median progression-free survival (PFS) time was 11 months and the median overall survival (OS) time was 23 months. The 5-year PFS and OS rates were 22% and 25%, respectively. On the multivariate analyses, less than 4 involved lymph nodes was predictive of a better PFS and OS.

Conclusion

HDC with CTCb for MBC has acceptable toxicity; however, this treatment does not show a survival benefit.

Citations

Citations to this article as recorded by

Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Jung Sun Park, Cheolwon Suh
The Korean Journal of Medicine.2021; 96(6): 501. CrossRef

8,982 View
48 Download
1 Crossref

Predictive Value of Preoperative Serum CEA, CA19-9 and CA125 Levels for Peritoneal Metastasis in Patients with Gastric Carcinoma: Gun Ick Hwang, Chang Hak Yoo, Byung Ho Sohn, Jun Ho Shin, Yong Lai Park, Heung Dai Kim, Yong Shin Kim, Won Kon Han, Won Kil Pae; Cancer Res Treat. 2004;36(3):178-181. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.178

Abstract PDF PubReader ePub

Purpose

Peritoneal metastasis is a crucial factor for the prognosis in gastric cancer, but its diagnosis is difficult before laparotomy. This study analyzed the usefulness of diagnostic imaging and various tumor markers in the detection of peritoneal metastasis in gastric cancer.

Materials and Methods

The sera from 768 patients with gastric cancer were measured for CEA, CA19-9 and CA125 levels using a commercial immunoradiometric assay. All the patients underwent diagnostic imaging with computed tomography (CT) and ultrasound (US) before laparotomy.

Results

Preoperative levels of CEA, CA19-9 and CA125 were above the cut-off levels in 15.4%, 8.7% and 5.7% of all cases, respectively. Eighty-eight patients were diagnosed with peritoneal metastasis by laparotomy. CT and US revealed peritoneal dissemination in 15 of 88 patients (17%). Among the three tumor markers, CA19-9 and CA125 showed similar detection rates of peritoneal metastasis (37.5% and 38.6%, respectively). In particular, the serum CA125 levels showed the best sensitivity (38.6%), specificity (98.4%), and diagnostic accuracy (91.5%), and the highest odd ratio (24.46, 95% CI: 11.17~53.57) for predicting peritoneal metastasis among the markers tested. CEA did not add significant predictive information (p=0.471).

Conclusion

Preoperative serum CA19-9 and CA125 levels may provide a predictable value in determining peritoneal metastasis in patients with gastric cancer.

Citations

Citations to this article as recorded by

Prognostic significance of serum tumor markers in various pathologic subtypes of gastric cancer
Chuhong Pang, Yubo Ma, Wenyi Shi, Mengli Zi, Jinxia Chen, Chen Liang, Xiao Li, Zhuo Liu, Yian Du
Journal of Gastrointestinal Surgery.2024; 28(5): 694. CrossRef
Development of Panel of Three-Dimensional Biomarkers to Identify Gastric Carcinoma and Precancerous Lesions of the Stomach - An Analytical Cross-Sectional Study
Sandhya Karra, Ramanan Sinduja, Balakrishnan Gurushankari, T. P. Elamurugan, Thulasingam Mahalakshmy, Vikram Kate, Nivedita Nanda, Nachiappa Ganesh Rajesh, Murugesan Rajeswari, Ruben Raj, Gomathi Shankar
Indian Journal of Clinical Biochemistry.2024;[Epub] CrossRef
Usefulness of Diagnostic Staging Laparoscopy for Advanced Gastric Cancer
Kozo Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Shohei Eto, Toshiaki Yoshimoto
The American Surgeon™.2023; 89(4): 685. CrossRef
Intraoperative Pathological Evaluation of Suspicious Peritoneal Nodules for Surgical Decision-making in Gastric Cancer
Chen Wang, Junjie Zhao, Jie Sun, Chenyu Tian, Zhiqiang Dai, Jingdong Liu, Chengbo Ji, Dan Liu, Xuefei Wang, Haojie Li, Yihong Sun
Journal of Gastrointestinal Surgery.2023; 27(8): 1545. CrossRef
Development and validation of a CT radiomics and clinical feature model to predict omental metastases for locally advanced gastric cancer
Ahao Wu, Changlei Wu, Qingwen Zeng, Yi Cao, Xufeng Shu, Lianghua Luo, Zongfeng Feng, Yi Tu, Zhigang Jie, Yanyan Zhu, Fuqing Zhou, Ya Huang, Zhengrong Li
Scientific Reports.2023;[Epub] CrossRef
Nomogram for predicting overall survival after curative gastrectomy using inflammatory, nutritional and pathological factors
Qi Wang, Qiang Zhang, Jiankang Zhu, Linchuan Li, Runzhi Zeng, Huanxin Ding, Zhenmin Li, Tianyi Feng, Ruiqi Hao, Guangyong Zhang
Clinical and Translational Oncology.2023; 26(4): 1001. CrossRef
Does CA 125 Predict Peritoneal Dissemination in Patients with Gastric Cancer?
Murat Güner, Tayfun Kaya, Cengiz Aydın
Indian Journal of Surgery.2022; 84(4): 779. CrossRef
Comparison of clinical-computed tomography model with 2D and 3D radiomics models to predict occult peritoneal metastases in advanced gastric cancer
Jiang Huang, Yidi Chen, Yuying Zhang, Jinhuan Xie, Yiqiong Liang, Wenzhao Yuan, Ting Zhou, Ruizhi Gao, Rong Wen, Yuwei Xia, Liling Long
Abdominal Radiology.2022; 47(1): 66. CrossRef
Clinical effect of 64-row spiral CT combined with multiple tumor markers in the diagnosis of gastric cancer and its effect on accuracy
Libo YU, Lei LI, Meiying YU, Jun CHEN
Minerva Medica.2022;[Epub] CrossRef
Investigation of serum markers of esophageal squamous cell carcinoma based on machine learning methods
Zhifeng Ma, Ting Zhu, Haiyong Wang, Bin Wang, Linhai Fu, Guangmao Yu
The Journal of Biochemistry.2022; 172(1): 29. CrossRef
Construction of a Nomogram Model for Predicting Peritoneal Dissemination in Gastric Cancer Based on Clinicopathologic Features and Preoperative Serum Tumor Markers
Dandan Bao, Zhangwei Yang, Senrui Chen, Keqin Li, Yiren Hu
Frontiers in Oncology.2022;[Epub] CrossRef
Novel CT based clinical nomogram comparable to radiomics model for identification of occult peritoneal metastasis in advanced gastric cancer
Lili Wang, Peng Lv, Zhen Xue, Lihong Chen, Bin Zheng, Guifang Lin, Weiwen Lin, Jingming Chen, Jiangao Xie, Qing Duan, Jun Lu
European Journal of Surgical Oncology.2022; 48(10): 2166. CrossRef
Predicting peritoneal carcinomatosis of gastric cancer: A simple model to exempt low-risk patients from unnecessary staging laparoscopy
Zhemin Li, Guangmin Guan, Zining Liu, Jiazheng Li, Xiangji Ying, Fei Shan, Ziyu Li
Frontiers in Surgery.2022;[Epub] CrossRef
Collagen Family as Promising Biomarkers and Therapeutic Targets in Cancer
Laura Necula, Lilia Matei, Denisa Dragu, Ioana Pitica, Ana Neagu, Coralia Bleotu, Carmen C. Diaconu, Mihaela Chivu-Economescu
International Journal of Molecular Sciences.2022; 23(20): 12415. CrossRef
Risk factors associated with peritoneal carcinomatosis of gastric cancer in staging laparoscopy: A systematic review and meta-analysis
Guangmin Guan, Zhemin Li, Qi Wang, Xiangji Ying, Fei Shan, Ziyu Li
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical Applications of Liquid Biopsy in Gastric Cancer
Mihaela Chivu-Economescu, Laura Necula, Lilia Matei, Denisa Dragu, Coralia Bleotu, Carmen C. Diaconu
Frontiers in Medicine.2021;[Epub] CrossRef
A Novel Nomogram Integrated with Inflammation-Based Factors to Predict the Prognosis of Gastric Cancer Patients
Xueping Wang, Minjie Mao, Shihao Zhu, Shan Xing, Yiling Song, Lin Zhang, Peidong Chi
Advances in Therapy.2020; 37(6): 2902. CrossRef
Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma

Yao Huang, Jianxing Zeng, Teng Liu, Xinju Lin, Pengfei Guo, Jinhua Zeng, Weiping Zhou, Jingfeng Liu
OncoTargets and Therapy.2020; Volume 13: 4559. CrossRef
Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers
Yanyan Chen, Quan Zhou, Haiyong Wang, Wei Zhuo, Yongfeng Ding, Jun Lu, Guanghao Wu, Nong Xu, Lisong Teng
Cancers.2020; 12(8): 2236. CrossRef
A nomogram based on glycomic biomarkers in serum and clinicopathological characteristics for evaluating the risk of peritoneal metastasis in gastric cancer
Junjie Zhao, Ruihuan Qin, Hao Chen, Yupeng Yang, Wenjun Qin, Jing Han, Xuefei Wang, Shifang Ren, Yihong Sun, Jianxin Gu
Clinical Proteomics.2020;[Epub] CrossRef
Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading
Bayazid Ghaderi, Hamoon Moghbel, Nasrin Daneshkhah, Asrin Babahajian, Farshad Sheikhesmaeili
Journal of Gastrointestinal Cancer.2019; 50(3): 525. CrossRef
Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers
Caleb Harris, Vikas Ostwal, Dilip Harindran Vallathol, Rohit Dusane, Sarika Mandavkar, Shraddha Patkar, Anant Ramaswamy, Shailesh V. Shrikhande
South Asian Journal of Cancer.2019; 08(03): 166. CrossRef
Clinical Significance of Serum CA125, CA19-9, CA72-4, and Fibrinogen-to-Lymphocyte Ratio in Gastric Cancer With Peritoneal Dissemination
Chao Huang, Zitao Liu, Li Xiao, Yongqiang Xia, Jun Huang, Hongliang Luo, Zhen Zong, Zhengming Zhu
Frontiers in Oncology.2019;[Epub] CrossRef
A new score for screening of malnutrition in patients with inoperable gastric adenocarcinoma
Ali Esfahani, Mohammad Hossein Somi, Mohammad Asghari Jafarabadi, Alireza Ostadrahimi, Mousa Ghayour Nahand, Zahra Fathifar, Akram Doostzadeh, Zohreh Ghoreishi
Japanese Journal of Clinical Oncology.2017; 47(6): 475. CrossRef
Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer
Xiao-dong Chen, Chen-chen Mao, Rui-sen Wu, Wei-teng Zhang, Ji Lin, Xiang-wei Sun, Chu-huai Chi, Neng Lou, Peng-fei Wang, Xian Shen, Guan-bao Zhu, Shu-rong Shen, Valli De Re
PLOS ONE.2017; 12(4): e0175074. CrossRef
Tumor volume increases the predictive accuracy of prognosis for gastric cancer: A retrospective cohort study of 3409 patients
Zhen Liu, Peng Gao, Shushang Liu, Gaozan Zheng, Jianjun Yang, Li Sun, Liu Hong, Daiming Fan, Hongwei Zhang, Fan Feng
Oncotarget.2017; 8(12): 18968. CrossRef
Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases
Fan Wu, Chunmei Shi, Riping Wu, Zhiqing Huang, Qiang Chen
Oncotarget.2017; 8(44): 78120. CrossRef
Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options
Nina Sluiter, Erienne de Cuba, Riom Kwakman, Geert Kazemier, Gerrit Meijer, Elisabeth Atie te Velde
Clinical & Experimental Metastasis.2016; 33(5): 401. CrossRef
The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)
LIANG LIU, JINFENG XIANG, RUFU CHEN, DELIANG FU, DEFEI HONG, JIHUI HAO, YIXIONG LI, JIANGTAO LI, SHENGPING LI, YIPING MOU, GANG MAI, QUANXING NI, LI PENG, RENYI QIN, HONGGANG QIAN, CHENGHAO SHAO, BEI SUN, YONGWEI SUN, MIN TAO, BOLE TIAN, HONGXIA WANG, JIA
International Journal of Oncology.2016; 48(3): 900. CrossRef
Clinical Significance of CA125 Level with Clinicopathological Variables and Peritoneal Dissemination in Patients with Gastric Carcinoma
Laila Shirin
Gastroenterology & Hepatology: Open Access.2016;[Epub] CrossRef
Prognostic values of normal preoperative serum cancer markers for gastric cancer
Fan Feng, Li Sun, Zhen Liu, Shushang Liu, Gaozan Zheng, Guanghui Xu, Man Guo, Xiao Lian, Daiming Fan, Hongwei Zhang
Oncotarget.2016; 7(36): 58459. CrossRef
Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients
Dae Hoon Kim
World Journal of Gastroenterology.2015; 21(4): 1216. CrossRef
Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association
Hideaki Shimada, Tamaki Noie, Manabu Ohashi, Koji Oba, Yutaka Takahashi
Gastric Cancer.2014; 17(1): 26. CrossRef
Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer
Hao Lai, Qinwen Jin, Yuan Lin, Xianwei Mo, Bo Li, Ke He, Jiansi Chen
Tumor Biology.2014; 35(10): 10547. CrossRef
Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer
Shu-Bo Tian, Jian-Chun Yu, Wei-Ming Kang, Zhi-Qiang Ma, Xin Ye, Zhan-Jiang Cao, Chao Yan
Asian Pacific Journal of Cancer Prevention.2014; 15(15): 6295. CrossRef
Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination
Shigenobu Emoto, Hironori Ishigami, Hiroharu Yamashita, Hironori Yamaguchi, Shoichi Kaisaki, Joji Kitayama
Gastric Cancer.2012; 15(2): 154. CrossRef
Pilot Feasibility Study of Neoadjuvant Chemoradiotherapy with S-1 in Patients with Locally Advanced Gastric Cancer Featuring Adjacent Tissue Invasion or JGCA Bulky N2 Lymph Node Metastases
Tatsushi Inoue, Shinichi Yachida, Hisashi Usuki, Tomoki Kimura, Masanobu Hagiike, Keiichi Okano, Yasuyuki Suzuki
Annals of Surgical Oncology.2012; 19(9): 2937. CrossRef
Serum levels of CA19-9 may be as an indicator for metastases in patients with non-small cell lung cancer
Xing’an Liu, Guoyong Shan, Song Zhang, Kaijian Lei
The Chinese-German Journal of Clinical Oncology.2011; 10(12): 692. CrossRef
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
HanByoul Cho, Hye Won Hur, Sang Wun Kim, Sung Hoon Kim, Jae Hoon Kim, Young Tae Kim, Kook Lee
Cancer Immunology, Immunotherapy.2009; 58(1): 15. CrossRef

10,920 View
78 Download
39 Crossref

Expression of CD4 Molecules on Human Bone Marrow Cells and Lymphoma / leukemia Cell Lines: Tae Jin Kim, Doo Hyun Chung, Kyeong Cheon Jung, Sun Shin Kim, Jang Hee Hahm, Kuhn Kuk Lee, Seong Hoe Park; J Korean Cancer Assoc. 1995;27(6):1008-1017.

PDF

2,324 View
16 Download

First
Prev
Page of 1
Next
Last

Search